The authors reported that in patient-derived organoid models in vitro and patient-derived xenograft models in vivo, mitochondrial calcium uniporter (MCU)-high PDAC demonstrated increased sensitivity to SLC7A11 inhibition compared with MCU-low tumors.
[Cancer Research]
